106 related articles for article (PubMed ID: 1936490)
1. Hypofibrinolysis and insulin-resistance.
Juhan-Vague I; Vague P
Diabete Metab; 1991 May; 17(1 Pt 2):96-100. PubMed ID: 1936490
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.
Scelles V; Raccah D; Alessi MC; Vialle JM; Juhan-Vague I; Vague P
Diabete Metab; 1992; 18(1):38-42. PubMed ID: 1563535
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
4. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.
Juhan-Vague I; Alessi MC; Morange PE
Ann Med; 2000 Dec; 32 Suppl 1():78-84. PubMed ID: 11209987
[TBL] [Abstract][Full Text] [Related]
5. PAI-1, obesity, insulin resistance and risk of cardiovascular events.
Juhan-Vague I; Alessi MC
Thromb Haemost; 1997 Jul; 78(1):656-60. PubMed ID: 9198234
[TBL] [Abstract][Full Text] [Related]
6. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels.
Juhan-Vague I; Alessi MC; Raccah D; Aillaud MF; Billerey M; Ansaldi J; Philip-Joet C; Vague P
Thromb Haemost; 1992 Jan; 67(1):76-82. PubMed ID: 1615488
[TBL] [Abstract][Full Text] [Related]
7. Hypofibrinolysis and the insulin resistance syndrome.
Vague P; Raccah D; Scelles V
Int J Obes Relat Metab Disord; 1995 May; 19 Suppl 1():S11-5. PubMed ID: 7550531
[TBL] [Abstract][Full Text] [Related]
8. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
[TBL] [Abstract][Full Text] [Related]
9. Fat cell function and fibrinolysis.
Alessi MC; Morange P; Juhan-Vague I
Horm Metab Res; 2000; 32(11-12):504-8. PubMed ID: 11246816
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
11. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?
Yudkin JS
Diabetes Care; 1999 Apr; 22 Suppl 3():C25-30. PubMed ID: 10189559
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
13. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
Banfi C; Mussoni L; Tremoli E
Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
[TBL] [Abstract][Full Text] [Related]
14. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
Herlihy OM; Barrow BA; Grant PJ; Levy JC
Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
[TBL] [Abstract][Full Text] [Related]
15. Hypertension as a metabolic disorder--an overview.
Smith U; Gudbjörnsdottir S; Landin K
J Intern Med Suppl; 1991; 735():1-7. PubMed ID: 2043218
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Carmassi F; De Negri F; Fioriti R; De Giorgi A; Giannarelli C; Fruzzetti F; Pedrinelli R; Dell'Omo G; Bersi C
Thromb Res; 2005; 116(3):207-14. PubMed ID: 15935829
[TBL] [Abstract][Full Text] [Related]
17. Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis.
Eriksson MA; Rask E; Johnson O; Carlström K; Ahrén B; Eliasson M; Boman K; Söderberg S
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):625-32. PubMed ID: 18832901
[TBL] [Abstract][Full Text] [Related]
18. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.
Juhan-Vague I; Vague P; Alessi MC; Badier C; Valadier J; Aillaud MF; Atlan C
Diabete Metab; 1987 Jul; 13(3 Pt 2):331-6. PubMed ID: 3115843
[TBL] [Abstract][Full Text] [Related]
19. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor (PAI) in obese men and obese women.
Cucuianu M; Lanczek M; Roman S
Rom J Intern Med; 1993; 31(3):183-92. PubMed ID: 8130756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
